Tudor Investment Corp
ALDX icon

Tudor Investment Corp’s Aldeyra Therapeutics ALDX Stock Holding History

Tudor Investment Corp’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-14,000
Closed -$193K – 992
2018
Q3 		$193K Buy
+14,000
New +$114K ﹤0.01% 972

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tudor Investment Corp's ALDX Position: Q4 2018 in Review

Tudor Investment Corp sold out of Aldeyra Therapeutics (ALDX) in Q4 2018, closing a stake of 14,000 shares — an estimated $193K sold.

Tudor Investment Corp first reported a position in ALDX in Q3 2018 and held it in 1 quarter. The position peaked at $193K in Q3 2018. 77 funds tracked by Wall St. Rank hold ALDX as of Q4 2018.

  • Tudor Investment Corp reported no remaining Aldeyra Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Tudor Investment Corp sold 14,000 Aldeyra Therapeutics shares in Q4 2018, an estimated $193K.
  • Tudor Investment Corp first reported a position in Aldeyra Therapeutics in Q3 2018 and held it in 1 quarter.
  • Tudor Investment Corp's Aldeyra Therapeutics position peaked at $193K in Q3 2018.
  • 77 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2018.

Based on Tudor Investment Corp's 13F filing for Q4 2018, filed 14 Feb 2019.